Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group

Hall, Matthew D; Terezakis, Stephanie A.; Lucas, John T.; Gallop‐Evans, Eve; Dieckmann, Karin; Constine, Louis S.; Hodgson, David C.; Flerlage, Jamie E.; Metzger, Monika L.; Hoppe, B.S.

doi:10.1016/j.ijrobp.2021.07.1716

Cited by 14 publications

(5 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, patients who underwent radiation therapy had a higher survival rate than those who did not underwent radiation therapy; this is consistent with the results of a previous study [29]. However, previous study results show that event-free survival (EFS) rates favor patients receiving radiotherapy by up to 10% [30,31]. This may be because all major children and several adult in HL research groups have followed a response-based treatment adaptation and toxicity-saving model over the past thirty years by reducing or eliminating RT.…”

Section: Discussionsupporting

confidence: 89%

A Nomogram for Predicting Cancer-Specific Survival of Hodgkin lymphoma in Children and Young Adulthood: an Observational Study using SEER Population-based Data

Zhang

Liu

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Hodgkin lymphoma (HL) is the most common neoplasm in children and young adults; GLOBOCAN 2020 shows a total of 83,087 new cases and 23,376 deaths of HL worldwide. This study developed a prognostic nomogram of HL in children and young adulthood for purpose to discuss independent risk factors for HL patients with the Surveillance, Epidemiology and End Results (SEER) database. Methods We downloaded the clinicopathological data of children and young adulthood with HL from 1975 to 2020 in the SEER database. Univariate and multivariate Cox regression analyses were used to screen children and young adulthood independent risk factors for Cancer-Specific Survival (CSS). These risk factors were used to construct a nomogram to predict the CSS of children and young adulthood with HL. A series of validation methods, including calibration curve, consistency index (C-index), and area under the receiver operating characteristic curve (AUC), were used to validate the accuracy and reliability of the prediction model. Decision curve analysis (DCA) was used to validate the clinical application efficacy of predictive models. All patients were divided into low- and high-risk groups based on the nomogram score. Kaplan-Meier curve and log-rank test were used to compare survival differences between the two groups. Results A total of 13,529 children and young adulthood with HL were included. Univariate and multivariate analysis suggested that Age, sex, stage, radiation, chemotherapy, histological type were independent risk factors. Nomograms were established based on these factors to predict 3-, 5-, and 10-years CSS of children and young adulthood with HL. The calibration plots showed that the predicted value was highly consistent with the actual value. In the training and validation cohorts, the C-index was 0.682 (0.665–0.700) and 0.694 (0.672–0.716), respectively. The AUC of the training and validation cohorts also showed similar results. The DCA showed that the nomogram had good clinical value. Conclusion We constructed a new nomogram to predict the CSS of HL in children and young adults. This predictive model is accurate and reliable and can help doctors and patients develop clinical strategies.

show abstract

Section: Discussionsupporting

confidence: 89%

A Nomogram for Predicting Cancer-Specific Survival of Hodgkin lymphoma in Children and Young Adulthood: an Observational Study using SEER Population-based Data

Zhang

Liu

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The data are an extraordinary resource, and it remains our responsibility to provide the informatics infrastructure to move imaging and radiation oncology objects for study to a common platform in a public domain linked to pathology and genetic information as a DICOM object linked to the platform in a manner similar to an image. This has the potential of being a worldwide resource for all to learn [25][26][27][28][29][30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Modern Dosimetry in Radiation Oncology Clinical Trials

Smith,

Ding,

Bishop-Jodoin

et al. 2023

Advances in Dosimetry and New Trends in Radiopharmaceuticals

View full text Add to dashboard Cite

Clinical trials in radiation oncology are the best vehicle to optimize our strengths in therapeutic technology, define progress in our field, and improve patient outcome. Trials advance our knowledge in each disease site and provide us information to improve the radiation dose-volume for both tumor control and therapeutic sequelae to normal tissue. An increasing number of systemic and targeted therapies have been developed and are currently in early phase clinical trial design. Ultimately, these new therapies will need to be tested with standard-of-care therapy including radiation oncology. Therefore, during a study, it is essential that radiation therapy is delivered in a uniform and consistent manner for the credibility of the study. If the radiation therapy component of the study does not have a structure or management for maintaining therapeutic compliance, including a real-time data management strategy, it becomes difficult to trust the study outcome and apply the outcome to daily clinical practice. In this chapter, we review the strategy and process involved in the management of dosimetry in radiation oncology clinical trials and how this can impact clinical trial management, primary study endpoints, and the overall success of the study.

show abstract

“…Stages IA and IIA without bulk, and IVB have been consistently classified as low and high risk, respectively; all other stages have been classified in more than one risk category dependent on the pediatric trial. The International Staging Evaluation and Response Criteria Harmonization (SEARCH) initiative is working to standardize criteria for baseline disease involvement and for response in pediatric cHL 7,8 . Pediatric‐specific HL guidelines from the National Comprehensive Cancer Network update approaches in terms of stage and risk 9 …”

Section: Clinical State Of the Diseasementioning

confidence: 99%

“…The risk of RT‐related morbidity on pediatric HL survivors has been reduced with a comprehensive approach facilitated by FDG‐PET: irradiating fewer patients in frontline treatment using response‐adapted approaches; evolution from involved‐field to involved‐site, lesion‐based RT with smaller tailored radiation fields, and integrating highly conformal radiotherapy techniques 8,54 (Table 4). A significant reduction in normal tissue dose to breast, heart, and thyroid has been demonstrated with these changes 55 .…”

Section: Recent Findingsmentioning

confidence: 99%

See 1 more Smart Citation

Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Castellino,

Giulino‐Roth,

Harker‐Murray

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

The goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials include: (i) superior event‐free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high‐risk disease, (ii) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and (ii) the potential to select a population that can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead a National cancer Institute National Clinical Trials Network phase 3 trial to evaluate the combination of Bv/nivolumab in early‐stage disease. Ongoing advances in technology and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.

show abstract

Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group

Cited by 14 publications

References 81 publications

A Nomogram for Predicting Cancer-Specific Survival of Hodgkin lymphoma in Children and Young Adulthood: an Observational Study using SEER Population-based Data

A Nomogram for Predicting Cancer-Specific Survival of Hodgkin lymphoma in Children and Young Adulthood: an Observational Study using SEER Population-based Data

Modern Dosimetry in Radiation Oncology Clinical Trials

Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Contact Info

Product

Resources

About